Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.3.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.5.6 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.440NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.25NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.23.2 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AY.104 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.198NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EG.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XAFNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BC.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
P.1.17.1 (Gamma)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.2.3.16NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.41NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.1.375NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BL.1.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BN.1.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
AD.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.26.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.10.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XAY.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CY.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.3.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBTNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.1.12NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BQ.1.33NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.29NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.1.28NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CL.1.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BM.1.1.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBMNNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BF.34NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CB.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BR.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.1.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CL.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.2.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CH.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
EF.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BR.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BN.1.2.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CP.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.160.8NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
XBB.2.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BE.4.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
B.1.177.12NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BA.5.2.41NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BN.1.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
CA.3NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
BN.5NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-20489.8Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used